IONS Q3 2022 Earnings — Ionis Pharmaceuticals, Inc. Revenue & Financial Results | Market Cap Arena

IONSIonis Pharmaceuticals, Inc.

$12B

Q3 2022 Earnings

Healthcare Biotechnology

Income Statement

Revenue

$160M+20.0% YoY

Gross Profit

$158M99.1% margin

Operating Income

-$59M-37.0% margin

Net Income

-$47M-29.4% margin

EPS (Diluted)

$-0.33

QoQ Revenue Growth

+19.4%

Cash Flow

Operating Cash Flow

-$24M

Free Cash Flow

-$31M

Stock-Based Comp.

$24M

Balance Sheet

Total Assets

$2.4B

Total Liabilities

$1.8B

Stockholders' Equity

$594M

Cash & Equivalents

$315M

Year-over-Year Comparison

Metric	Current	Year Ago	Change
Revenue	$160M	$133M	+20.0%
Gross Profit	$158M	$130M	+21.7%
Operating Income	-$59M	-$86M	+31.1%
Net Income	-$47M	-$82M	+43.0%

Revenue Segments

Research and Development Revenue

$87M27%

Commercial

$72M23%

Collaborative Agreement Revenue

$69M22%

Spinraza Royalties

$62M19%

Eplontersen Joint Development Revenue

$18M6%

Product

$6M2%

Licensing and Other Royalties

$5M2%